Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-11-05
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $0.00.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $0.00.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $14.00K, a 30.00% decline from fiscal 2023.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $20.00K, a 100.00% increase from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $10.00K, a 96.67% decline from fiscal 2021.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $300.00K, a 89.29% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 3 quarters · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-09 | $0.00 derived: sum of 3 quarters · filed 2025-05-09 | $10.00K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $10.00K derived: sum of 3 quarters · filed 2025-03-17 | $14.00K 10-K · filed 2025-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $10.00K derived: sum of 2 quarters · filed 2024-11-04 | $14.00K 10-Q · filed 2024-11-04 | $14.00K derived: sum of 4 quarters · filed 2024-11-04 | |
| 2024-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $14.00K 10-Q · filed 2024-08-08 | $14.00K derived: sum of 3 quarters · filed 2024-08-08 | $14.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | $4.00K 10-Q · filed 2024-05-08 | $4.00K derived: sum of 2 quarters · filed 2024-05-08 | $4.00K derived: sum of 3 quarters · filed 2024-05-08 | $11.00K derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $7.00K derived: sum of 3 quarters · filed 2024-03-15 | $20.00K 10-K · filed 2024-03-15 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $7.00K derived: sum of 2 quarters · filed 2023-11-03 | $20.00K 10-Q · filed 2023-11-03 | $20.00K derived: sum of 4 quarters · filed 2023-11-03 | |
| 2023-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $20.00K 10-Q · filed 2023-08-08 | $20.00K derived: sum of 3 quarters · filed 2023-08-08 | $20.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | $13.00K 10-Q · filed 2023-05-09 | $13.00K derived: sum of 2 quarters · filed 2023-05-09 | $13.00K derived: sum of 3 quarters · filed 2023-05-09 | $13.00K derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $10.00K 10-K · filed 2023-03-16 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $10.00K 10-Q · filed 2022-11-09 | $76.00K derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $10.00K 10-Q · filed 2022-08-04 | $76.00K derived: sum of 3 quarters · filed 2024-03-15 | ||
| 2022-03-31 | $10.00K 10-Q · filed 2022-05-06 | $76.00K derived: sum of 2 quarters · filed 2024-03-15 | |||
| 2021-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $300.00K 10-K · filed 2024-03-15 | $257.00K 10-K · filed 2022-03-11 | ||
| 2021-09-30 | $234.00K 10-Q · filed 2021-11-05 | ||||
| 2020-12-31 | $2.80M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |